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Background: Although endoscopic biliary stents have been accepted as part of palliative therapy for cases of
malignant hilar obstruction, the optimal endoscopic management regime remains controversial. In this study, we
evaluated the safety and efficacy of placing a threaded stent above the sphincter of Oddi (threaded inside plastic
stents, threaded PS) and compared the results with those of other stent types.
Methods: Patients with malignant hilar obstruction, including those requiring biliary drainage for stent occlusion,
were selected. Patients received either one of the following endoscopic indwelling stents: threaded PS,
conventional plastic stents (conventional PS), or metallic stents (MS). Duration of stent patency and the incident of
complication were compared in these patients.
Results: Forty-two patients underwent placement of endoscopic indwelling stents (threaded PS = 12, conventional
PS = 17, MS = 13). The median duration of threaded PS patency was significantly longer than that of conventional
PS patency (142 vs. 32 days; P = 0.04, logrank test). The median duration of threaded PS and MS patency was not
significantly different (142 vs. 150 days, P = 0.83). Stent migration did not occur in any group. Among patients who
underwent threaded PS placement as a salvage therapy after MS obstruction due to tumor ingrowth, the median
duration of MS patency was significantly shorter than that of threaded PS patency (123 vs. 240 days).
Conclusions: Threaded PS are safe and effective in cases of malignant hilar obstruction; moreover, it is a suitable
therapeutic option not only for initial drainage but also for salvage therapy.Background
Unresectable hilar cholangiocarcinoma has a very poor
prognosis, with an overall survival of less than 6 months
[1,2]. Patients with malignant hilar biliary strictures
often present with obstructive jaundice, consequently
requiring biliary drainage. Endoscopic indwelling stents
have been widely used for the treatment of malignant
hilar obstructions [3-5]. Plastic stents (PS) are more
economical and easier to deliver and remove than
uncovered metallic stents (MS). However, the patency
duration of PS is generally shorter than that of
uncovered MS because of food impaction and ascending
bacterial infection from the duodenum [6-8].* Correspondence: osam@belle.shiga-med.ac.jp
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reproduction in any medium, provided the orRecently, various techniques have been reported for
stent insertion and stent refinement for the prolongation
of PS patency [9-14]. Placement of PS above the sphincter
of Oddi (inside stents) was reportedly superior to conven-
tional PS with respect to stent patency in cases of malig-
nant bile duct obstruction [15]. However, another study
showed that placement of the inside stent was associated
with high rates of stent migration and occlusion [16].
Therefore, the ideal choice of stent for use in cases of ma-
lignant hilar obstruction remains controversial.
To overcome the disadvantages of PS and to facilitate
delivery and removal of the so-called inside stents, we
first attach a nylon thread to a conventional PS and then
attempt the placement of this threaded stent above the
sphincter of Oddi (threaded inside plastic stents,
threaded PS). In this study, we retrospectively evaluated
and compared the safety and efficacy of threaded PSl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The design of threaded inside plastic stent (Threaded
PS). A nylon monofilament thread (size 3/0) is attached to the
conventional PS (Flexima, Boston Scientific) by using a puncher.
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ment in cases of malignant hilar obstruction.
Methods
Patients
Between April 2007 and March 2011, 42 cases with
unresectable malignant hilar obstruction underwent endo-
scopic indwelling stent placement, including threaded PS
(n = 12), conventional PS (n = 17), and MS (n = 13) place-
ment. Diagnosis was based on CT scans, MRCP, and
endoscopic retrograde cholangiography. Malignancy
was histologically confirmed in all patients. Hilar biliary
strictures were classified according to the Bismuth clas-
sification [17]: type I, obstruction at the bifurcation but
with communication between the left and right hepatic
ducts; type II, separate obstruction of the left and right
main hepatic ducts; type III, obstruction extending to at
least the secondary branches of either the right or left
hepatic duct, with the contralateral ductal system
remaining intact; and type IV, obstruction involving the
bilateral secondary branches or multifocal strictures.
All patients were considered to have unresectable ma-
lignancies after the evaluation of tumor extent, distinct
metastasis, and advanced age. Standard gemcitabine or
S-1-based chemotherapy was administered after success-
ful biliary drainage in patients with a good performance
status. No patient received radiation therapy. Follow-up
continued until patient death or study completion.
All patients provided informed written consent prior to
undergoing stent placement. The study was conducted in
agreement with the Declaration of Helsinki and received
approval (No. 21–91) from the ethics committee of Shiga
University of Medical Sciences and conformed to its
guidelines.
Endoscopic procedure for stent insertion
All endoscopic procedures were performed by two
experienced endoscopists. The patients were moderately
sedated (intravenous midazolam and pentazocine). For
all biliary stent placement techniques, JF260V or TJF-240
duodenoscopes (Olympus, Tokyo, Japan) were used. Ba-
sically, we firstly underwent endoscopic nasobilliary drain-
age for adequate drainage and accurate diagnosis, and
then, after a few days, inserted a suitable stent for a
particular stenosis. The type of stent that inserted initially
is MS or conventional PS in the early period of this study
(from April 2007 to September 2009), and threaded PS in
the late (from October 2009 to March 2011).
The stents were inserted over a guidewire after endo-
scopic retrograde cholangiography. The length of the
stent was selected so that either end of the stent was
approximately 1 cm beyond the tumor margin. Endo-
scopic sphincterotomy was performed additionally in
patients who received uncovered MS. Multiple stentswere placed in cases suffering from high-grade hilar
biliary strictures. Multiple MS were placed by a partial
stent-in-stent technique. For a unilateral stent place-
ment, the side for the proximal end of the stent was
judged by the surgeon’s discretion according to the in-
formation on lobar volume and angle.
The procedures used for the insertion of each stent
are described below.
1) Threaded PS placement
A double figure eight knot was used to attach a
nylon monofilament thread (size 3–0, 10 cm long) to
a conventional PS (7Fr, 5–10 cm, Flexima, Boston
Scientific, Natick, MA, USA) through a hole made
by a puncher (Figure 1). This threaded stent was
inserted by the standard procedure using a guidewire
and pusher catheter, and then placed above the
sphincter of Oddi with the attached nylon thread
remaining outside the papilla. This enabled the
surgeon to exchange stents easily by grabbing the
protruding thread (Figure 2).
2) Conventional PS
Double pigtail stents (7Fr or 8Fr, 5–10 cm, Cook
Medical Inc., Bloomington, IN, USA) or Flexima
stents (7Fr, 8.5Fr, or 10Fr, 5–10 cm, Boston
Scientific) were selected at the surgeon’s discretion.
This stent was inserted by the similar procedure as
threaded PS, and then placed across the sphincter of
Oddi with the distal end of the stent protruding into
the duodenum.
3) MS
Uncovered MS (ZEOSTENT plus or JOSTENT
SelfX, 4–8 cm; Zeon Medical Inc., Tokyo, Japan)
were selected at the surgeon’s discretion. The stent
was inserted using the delivery system, and then
placed above the sphincter of Oddi after the delivery
catheter was released.
Outcome measurement
For assessment of clinical response, successful cases of
biliary decompression were defined as those in which
serum total bilirubin declined to a normal level (<1.2 mg/
dL) or less than half of the level before stent placement.
Figure 2 Picture of threaded inside plastic stent (Threaded PS). A. The threaded inside stent before insertion B. Endoscopic view of the
thread, which is placed outside the papilla.
Inatomi et al. BMC Gastroenterology 2013, 13:31 Page 3 of 7
http://www.biomedcentral.com/1471-230X/13/31Stent occlusion was essentially diagnosed by endoscopic
retrograde cholangiography when a patient developed
cholangitis or jaundice after stent placement.
Efficacy of threaded PS placement as a salvage therapy in
cases of MS obstruction
Three patients who initially received MS underwent
threaded PS placement because of stent obstruction
caused by tumor ingrowth. On the other hand, one pa-
tient who initially received threaded PS underwent MS
placement because of stent obstruction caused by tumor
hemorrhage. To evaluate the efficacy of threaded PS
placement as a salvage therapy in cases of MS obstruc-
tion, the duration of stent patency was compared among
these patients.
Statistical analysis
Student’s t-test was used to compare baseline variables
between each group. The median duration of stent pa-
tency was analyzed by the Kaplan–Meier method, and
the results were compared by the logrank test. A P-value
of <0.05 was considered statistically significant. All sta-
tistical analyses were performed with GraphPad PRISM
version 4.03 software (MDF Co., Ltd., Tokyo, Japan).
Results
Patient characteristics
Patient characteristics are presented in Table 1. There
were no significant differences in age, sex, cause of bil-
iary obstruction, Bismuth classification, and the presence
or absence of chemotherapy among the three groups.
Multiple stent placement was attempted only in thethreaded PS and MS groups, and there was no signifi-
cant difference in the number of patients (threaded PS:
n = 2, MS: n = 4).Overall stent patency
All procedures for stent insertion were successful in
each group. The median duration of stent patency was
significantly longer in the threaded PS group than in the
conventional PS group (142 days vs. 32 days; P < 0.05)
(Figure 3). On the other hand, the median duration of
stent patency in the threaded PS group was similar to
that in the MS group (142 days vs. 150 days; P = 0.83)
(Figure 4). Multiple stent placement and endoscopic
sphincterotomy were not significantly related to median
duration of stent patency in the threaded PS and MS
group patients (164 days with multiple stent placement
vs. 140 days without, P = 0.60; 153 days with endoscopic
sphincterotomy vs. 125 days without, P = 0.52).Salvage therapy
Three patients who had undergone MS placement
received threaded PS because of stent obstructions caused
by tumor ingrowths (Patient 1, 2, 4 in Table 2). The over-
view images and durations of threaded PS and MS patency
in these patients, who underwent threaded PS placement
as a salvage therapy, are shown in Table 3. The mean dur-
ation of MS patency (first intervention) was shorter than
that of threaded PS patency in these patients (123 vs. 240
days). On the other hand, one patient underwent MS
placement after threaded PS obstruction caused by tumor
hemorrhages; of these, the duration of MS patency was








Male 7 8 7
Female 5 9 6
Age (years) mean ± SD 67.5 ± 11.7 66.1 ± 12.2 69.2 ± 13.2
Diagnosis
Bile duct cancer 5 6 7
Gall bladder cancer 4 8 4
Others 3 3 2
Bismuth classification
Type I 4 6 4
Type II 1 1 3
Type III 2 2 2
Type IV 5 8 4
Serum total bilirubin (mg/dl) mean ± SD 7.5 ± 5.6 6.2 ± 2.9 5.4 ± 3.2
Chemotherapy received * 5 (50%) 11 (65%) 4 (31%)
Gemcitabine 4 7 2
S-1 1 7 4
* Chemotherapy include combined therapy of gemcitabine and S-1.
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days (Patient 7 in Table 2).Complications
Threaded PS placement in an appropriate position be-
tween the stenosis and sphincter of Oddi was technically
easy because the position was adjusted by grasping the
attached thread with a forceps after the stent was released
from the scope. There were no threaded PS migrations
even in cases that received multiple stents.Figure 3 Cumulative patency durations of the plastic stents
(PS) and the threaded inside plastic stents (Threaded PS).
Kaplan–Meier estimation of the cumulative durations of stent
patency in the conventional PS (solid line; median duration, 32 days)
and threaded PS groups (dotted line; median duration, 142 days).Major complication such as perforation or bleeding did
not occur in cases that received endoscopic sphincterotomy.
Discussion
The advantages of this custom-made stent include uncom-
plicated positioning, which is not across the sphincter of
Oddi, and ease of fabrication and removal, which is
facilitated by grabbing the attached thread. In addition,
threaded PS placement and exchange can be performed
without endoscopic sphincterotomy, which increases the
risk of complications like bleeding, perforation, pancreatitis,Figure 4 Cumulative patency durations of the metallic stents
(MS) and the threaded inside plastic stents (Threaded PS).
Kaplan–Meier estimation of the cumulative durations of stent
patency in the MS (solid line; median duration, 150 days) and
threaded PS groups (dotted line; median duration, 142 days).














1 Bile duct 2 IV IV N N Y No 350 Death
2 Bile duct 2 IV IV N Y Y No 300 Death
3 Gall bladder 0 IV I N N N GEM 270 Obstruction
4 Bile duct 0 IV IV N Y Y GEM 72 Obstruction
5 Bile duct 1 IV IV N N Y No 108 Death
6 Pancreas 1 IV I Y N N GEM 56 Obstruction
7 Gall bladder 3 IV II Y N N No 6 Obstruction by
Coagulation
8 Gall bladder 1 IV III N N N S-1 127 Obstruction
9 Bile duct 2 III III Y N N GEM 41 Death
10 Pancreas 2 IV I Y N N No 32 Death
11 Gall bladder 1 IV IV N N N No 80 Obstruction
12 Pancreas 2 III I Y N N No 290 Alive
EST, endoscopic sphincterotomy; GEM, gemcitabine.
* These cases have already received endoscopic sphincterotomy in the earlier stent placement of MS or PS before threaded PS insertion.
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showed that the median duration of threaded PS patency
was longer than that of conventional PS patency, and that
there was no significant difference between the duration of
threaded PS and MS patency.
Although conventional PS is still widely used for endo-
scopic biliary drainage, it sometimes requires frequent
stent exchanges at intervals of 1–4 months because of
stent obstruction with biliary sludge [21,22]. The main
reasons for PS obstruction seem to be the smaller stent
diameter and the bacterial biofilm created by ascending
infection from the duodenum, leading to biliary sludge
formation [7,18]. Given that the threaded PS diameter in
our study was only 7 Fr, its placement above the intact
sphincter of Oddi presumably avoided this duodenobiliary
reflux, leading to longer patency.
The efficacy of inside stents (without an attached
thread) in cases of malignant bile duct obstruction has
been investigated in other studies. In a randomized clinical
trial, Pedersen et al. reported that the median patency
duration of stents placed above the sphincter of Oddi was
comparable to that of stents placed across the sphincter of
Oddi [16]. However, the migration rate of stents placed
above the sphincter of Oddi was 58% in their study. On
the other hand, Uchida et al. reported that the median
patency duration of stents placed above the sphincter ofTable 3 The durations of stent patency for three cases
underwent threaded PS placement after MS occlusion
MS patency (Days) Post-salvage patency (Days)
Case 1 85 350
Case 2 234 300
Case 3 59 72Oddi was superior to that of stents placed across the
sphincter of Oddi (255 vs. 82 days), and the respective oc-
clusion rates were 37.5% and 93.8% [15]. Although their
results with respect to stent patency were satisfactory,
endoscopic sphincterotomy was required for stent ex-
change in most cases of stent occlusion.
In our study, four cases in the threaded PS group had
received initial treatment with MS, PS or endoscopic nasal
drainage with endoscopic sphincterotomy. Although stent
patency was not significantly different between patients
who do or do not undergo endoscopic sphincterotomy in
all cases that underwent threaded PS placement, the rate
of complications, such as bleeding, perforation and pan-
creatitis, is reportedly 1%–10% [19,23,24]. Therefore, this
option should be avoided wherever possible.
MS with larger diameters have been developed during
the past two decades [25,26], and these have proven to
possess longer durations of patency than those of conven-
tional PS [13,27,28]. In a randomized controlled study,
Wagner et al. reported superior performance of uncovered
MS in cases of malignant hilar obstruction; furthermore,
they found that the occlusion rate of uncovered MS was
lower than that of PS (18.9% vs. 50%) [3]. However, clin-
ical problems with MS placement often occur with respect
to cost, stent occlusion by tumor ingrowth or overgrowth
and mucosal hyperplasia induced by chronic inflammation
[29,30]. Additionally, endoscopic sphincterotomy is neces-
sary for MS placement in most cases. In the present study,
the duration of threaded PS patency was shown to be
superior to that of PS patency and noninferior to that of
MS patency.
In patients who receive MS, another problem is
reintervention in cases of stent occlusion. Uncovered MS
cannot be removed and are difficult to insert as a second
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because the first stent is often deployed within the bile
duct lumen [31]. In the present study, we also evaluated
the efficacy of threaded PS placement used as a second
mode of drainage in cases of MS obstruction. Our results
showed that the duration of threaded PS patency was
appreciably longer than that of MS patency in all patients.
The cause of occlusion in these patients was rapid tumor
ingrowth. In contrast, threaded PS quickly occluded
because of coagulation caused by tumor hemorrhage in
one patient; he received MS as a second mode of drainage.
These results suggest that threaded PS are probably su-
perior to MS only for tumors with certain biological
characteristics. Moreover, overall survival of these 3
patients was an average of 280 days despite tumor pro-
gression. Therefore, we recommend threaded PS place-
ment in patients with aggressive tumor that progress
locally in the biliary duct without distant metastasis.
The present analysis was retrospective; therefore, selec-
tion bias may have affected the outcome, although all cases
in this study were consecutive and the same endoscopists
made all decisions regarding stent type during the data col-
lection period. In addition, the study sample was small.
Further studies, such as randomized controlled studies
with a larger study sample, are warranted.
Although surgical resection is the only curative option
for hilar cholangiocarcinoma, 5-year survival following
resection reportedly ranges from 20% to 40% [32]. Most
patients need palliative therapy such as endoscopic
drainage to prolong survival with a good quality of life
[26,33].
Therefore, endoscopists should select the type of
drainage on the basis of a patient’s performance status,
their expected survival, the technical difficulty, and the
characteristics of stent occlusions.
Conclusions
In conclusion, our data showed that threaded PS place-
ment was safe and effective in cases of malignant hilar
obstruction. It can be a suitable therapeutic option not
only for initial drainage but also for salvage therapy.
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